Making clothing brands and cosmetics, teaming up with influencers… Cosmax pushes deeper into the Chinese mainland
Predicted impact: Low
China expansion strategy feature; similar coverage already ran in recent days, no concrete figures.
192820 · KOSPI · ₩192820 · 코스맥스
Predicted impact: Low
China expansion strategy feature; similar coverage already ran in recent days, no concrete figures.
Predicted impact: Low
Interview with China unit stating ₩1T China sales goal by 2030; vague, long-term, not formal guidance.
Predicted impact: Low
Predicted impact: Low
Raw material partnership and eco-friendly sourcing; no size or revenue impact disclosed.
Predicted impact: Low
Raw material sourcing plan; similar Cosmax news already reported.
Predicted impact: Low
Raw material cooperation on regulation and premium ingredients; no size given.
Predicted impact: Low
New brand marketing subsidiary already reported as 'GrowX' launch within 14 days; no size given.
Predicted impact: Low
New brand-building subsidiary GrowX; no size given, small versus ₩2.7T revenue.
Predicted impact: Low
Harvard research partnership for Cosmax; vague, no financial size disclosed.
Predicted impact: Low
Harvard research partnership and US subsidiary commentary; vague with no quantified impact.
Predicted impact: Low
Ex-employee hired by Shinsegae; a personnel move at another company with little Cosmax impact.
Predicted impact: Low
Harvard research collaboration is one of several similar partnership reports; small financial effect.
Predicted impact: Low
Harvard Medical School partnership already reported several times; no financial size disclosed.
Predicted impact: Low
Harvard research partnership; similar partnerships already reported in last 14 days.
Predicted impact: Low
Research tie-up with Harvard-affiliated hospital already reported several times in last 14 days; no financial size given.
Predicted impact: Low
Research tie-up with Harvard-linked institutions already reported in recent days; no financial size given.
Predicted impact: Low
Predicted impact: Low
Harvard bio drug partnership; repeat of earlier VIVA project coverage.
Predicted impact: Low
Harvard VIVA project for bio drugs; already reported, no financial size given.
Predicted impact: Low
Harvard medical partnership was already announced in the last 14 days.
Also known as: Cosmax / 코스맥스 / 192820 / KRX:192820
Source: KRX statistical information